COVID-19: Drugs in Development


The COVID-19 outbreak, which started in December 2019 in Wuhan City, China, was declared a "Public Health Emergency of International Concern" by the WHO on January 30, 2020. The outbreak was characterized as a pandemic on March 11, 2020.

Currently, there are no drugs to treat COVID-19, caused by the novel coronavirus SARS-CoV-2.

Listed below are companies that are in the race to find a treatment or vaccine for the novel coronavirus.

Subscribe to RTT Intelligent Investor for FREE 7-Day Trial with complete access to COVID-19 Drugs in Development Calendar.

Company Name
Current Stage
Next Milestone
Last Updated
Aerpio Pharmaceuticals, Inc.
Razuprotafib for the treatment of acute respiratory distress syndrome in adult patients w
phase 2 study (I-SPY COVID Trial)
Quantum Leap Healthcare Collaborative
Oragenics Inc.
TerraCoV2 Vaccine
Preclinical studies
Begin human clinical trials of TerraCoV2 vaccine by early 2021
Eli Lilly And Co.
LY-CoV555, an antibody therapeutic for treatment and prevention of COVID-19
Phase 3 trial OF LY-CoV555 for the prevention of SARS-CoV-2 infection and COVID-19 (BLAZE-2)
Privately-held AbCellera Biologics Inc., National Institute of Allergy and Infectious Diseases (NIAID) Vaccine Research Center
Cerecor Inc.
CERC-002 is under phase 2 proof-of-concept trial in patients with COVID-19 cytokine storm-induced Acute Respiratory Distress Syndrome
Top-line data expected in the fourth quarter of 2020
Moderna, Inc
mRNA-1273 Vaccine
Phase 2 study underway, Phase 3 study (COVE) began on July 27
Phase 3 COVE data to be available by Thanksgiving (November)
Immunic, Inc
IMU-838 for COVID-19.
Phase 2 study in combination with Tamiflu in adult patients with moderate-to-severe COVID-19 (IONIC)
Top-line data expected later in 2020
University Hospitals Coventry and Warwickshire NHS Trust
Anti-Addiction patch for extracorporeal treatment
Anti-Addiction patch to remove disease-causing antigens and to prevent the “cytokine storm” associated with the disease in severely ill patients is under research stage
Halberd Corporation and Gold River Productions Inc.
Merck & Co Inc.
V590, a SARS-CoV-2 vaccine candidate
Preclinical development
Clinical studies of V590 to start this year
The International AIDS Vaccine Initiative (IAVI)

Get Full Access to latest records of COVID-19 Drugs in Development Calendar by subscribing to RTT Intelligent Investor with FREE 7-Day Trial. (No Credit Card Required)

Editors Pick
Billionaire Warren Buffett's Berkshire Hathaway reported a profit for the second-quarter that increased 87 percent from last year, as the value of its investment portfolio increased with the stock market. But it took about $10 billion write down on the value of its Precision Castparts aircraft parts unit due to the impact of the COVID-19 pandemic. Operating profit declined 10 percent. Twitter has had preliminary talks with TikTok's Chinese owner ByteDance to buy the U.S. operations of the video-sharing app, the Wall Street Journal reported citing people familiar with the matter. Meanwhile, Microsoft has been the only company so far to say publicly it is pursuing TikTok. Pfizer said Friday it reached a multi-year deal with Gilead Sciences to manufacture and supply Gilead's investigational antiviral remdesivir for COVID-19 patients.